Free Trial

Immatics (IMTX) Competitors

Immatics logo
$7.12 +0.27 (+3.94%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$7.02 -0.09 (-1.33%)
As of 09/23/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMTX vs. IMVT, XENE, VKTX, OGN, KNSA, NAMS, BHC, GMTX, CGON, and MLYS

Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Immunovant (IMVT), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), CG Oncology (CGON), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry.

Immatics vs. Its Competitors

Immunovant (NASDAQ:IMVT) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Immatics had 3 more articles in the media than Immunovant. MarketBeat recorded 6 mentions for Immatics and 3 mentions for Immunovant. Immunovant's average media sentiment score of 0.58 beat Immatics' score of 0.29 indicating that Immunovant is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Immatics
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immatics has higher revenue and earnings than Immunovant. Immatics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$413.84M-$2.85-5.23
Immatics$168.65M5.13$16.47M-$0.65-10.95

Immunovant presently has a consensus target price of $33.60, indicating a potential upside of 125.50%. Immatics has a consensus target price of $15.00, indicating a potential upside of 110.67%. Given Immunovant's higher possible upside, equities analysts clearly believe Immunovant is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83
Immatics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Immunovant has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.

Immunovant has a net margin of 0.00% compared to Immatics' net margin of -59.29%. Immatics' return on equity of -15.60% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -80.99% -72.23%
Immatics -59.29%-15.60%-12.31%

Summary

Immatics beats Immunovant on 9 of the 15 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMTX vs. The Competition

MetricImmaticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$832.62M$3.16B$5.76B$10.51B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-10.9521.0476.0626.61
Price / Sales5.13252.06472.8291.51
Price / Cash28.0446.3537.4661.85
Price / Book1.399.7813.586.45
Net Income$16.47M-$52.73M$3.29B$271.57M
7 Day Performance18.08%3.16%1.83%2.61%
1 Month Performance25.13%4.69%4.02%7.28%
1 Year Performance-39.04%16.37%77.05%29.60%

Immatics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMTX
Immatics
2.8193 of 5 stars
$7.12
+3.9%
$15.00
+110.7%
-39.5%$832.62M$168.65M-10.95260
IMVT
Immunovant
2.0142 of 5 stars
$15.53
-3.9%
$33.60
+116.4%
-47.4%$2.82BN/A-5.45120Positive News
XENE
Xenon Pharmaceuticals
2.5363 of 5 stars
$35.99
-0.6%
$53.30
+48.1%
-5.9%$2.79B$7.50M-10.14210Positive News
VKTX
Viking Therapeutics
4.4153 of 5 stars
$24.08
-2.9%
$87.50
+263.4%
-61.6%$2.79BN/A-15.7420Analyst Forecast
OGN
Organon & Co.
4.5663 of 5 stars
$10.39
-2.5%
$17.33
+66.9%
-46.4%$2.77B$6.40B3.864,000Positive News
KNSA
Kiniksa Pharmaceuticals International
2.6524 of 5 stars
$36.56
-1.5%
$41.17
+12.6%
+47.6%$2.75B$423.24M914.23220Positive News
NAMS
NewAmsterdam Pharma
3.1389 of 5 stars
$24.12
-0.3%
$41.55
+72.2%
+72.4%$2.72B$45.56M-14.894Positive News
BHC
Bausch Health Cos
4.612 of 5 stars
$7.17
-1.2%
$9.00
+25.5%
-16.0%$2.69B$9.86B27.5820,700
GMTX
Gemini Therapeutics
N/A$59.82
-0.8%
N/A+27.8%$2.59BN/A-59.8230
CGON
CG Oncology
2.5467 of 5 stars
$34.60
+3.8%
$53.91
+55.8%
-4.3%$2.54B$1.14M-19.5561Insider Trade
MLYS
Mineralys Therapeutics
2.8337 of 5 stars
$36.21
-2.4%
$43.50
+20.1%
+228.8%$2.46BN/A-10.1728

Related Companies and Tools


This page (NASDAQ:IMTX) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners